<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/CINECAstyle.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-23T17:07:07Z</responseDate><request verb="GetRecord" identifier="oai:iris.unica.it:11584/266135" metadataPrefix="oai_dc">https://iris.unica.it/oai/request</request><GetRecord><record><header><identifier>oai:iris.unica.it:11584/266135</identifier><datestamp>2022-10-20T09:33:42Z</datestamp><setSpec>com_11584_207615</setSpec><setSpec>com_11584_111066</setSpec><setSpec>col_11584_265854</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
<dc:title>Sviluppo di vettori virali per la terapia genica della β−Talassemia</dc:title>
<dc:creator>CABRIOLU, ANNALISA</dc:creator>
<dc:subject>cassetta β-globinica</dc:subject>
<dc:subject>gene expression</dc:subject>
<dc:subject>gene therapy</dc:subject>
<dc:subject>lentiviral vector</dc:subject>
<dc:subject>terapia genica</dc:subject>
<dc:subject>vettori lentivirali</dc:subject>
<dc:subject>β-globin cassette</dc:subject>
<dc:subject>β−Talassemia</dc:subject>
<dc:subject>Settore MED/38 - Pediatria Generale e Specialistica</dc:subject>
<dc:description>Beta−thalassemia major is a severe congenital anemi for	 which there is presently no curative therapy other than allogeneic hematopoietic stem cell transplantation. This therapeutic option, however, applies only to the minority of thalassemia patients	who have an HLA−matched	bone marrow donor. Gene therapy by the delivery of a regulated globin gene to	autologous hematopoietic stem cells is an attractive  alternative approach as it is in principle	applicable to all thalassemic subjects.	Current vectors, althougheffective in correcting	thalassemia in	murine models	still suffer some drawbacks in terms of	safety	and also in	terms of low titer and expression. The	aim of this study was to assemble globin vectors improved in both these  aspects. Modifications of the globin cassette in	the intron2	and in the LCR of the beta-­‐globin gene	can increase the expression	of the globin gene without reducing the vector titer. We also examine the variegation in the expression among the different pools of transduce cells	 and we suppose that the presence of sequences with chromatin opening activity among the segments of b-­‐globin IVS2</dc:description>
<dc:date>2012-03-08</dc:date>
<dc:type>info:eu-repo/semantics/doctoralThesis</dc:type>
<dc:identifier>http://hdl.handle.net/11584/266135</dc:identifier>
<dc:language>ita</dc:language>
<dc:relation>numberofpages:57</dc:relation>
<dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
<dc:publisher>Università degli Studi di Cagliari</dc:publisher>
<dc:rights>license:Non specificato</dc:rights>
</oai_dc:dc></metadata></record></GetRecord></OAI-PMH>